Efficacy of a novel chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against four common tick species infesting dogs in Europe

Table 5 Arithmetic mean live Rhipicephalus sanguineus counts for dogs dosed once orally with sarolaner + moxidectin + pyrantel and efficacy relative to placebo (Study 6)

Count day	Placebo		1.2 mg/kg sarolaner + 24 µg moxidectin + 5 mg/kg pyrantel			Test statistic (vs placebo)
Count day	Mean	Range	Mean^a	Range	% Efficacy	Test statistic (vs placebo)
2	24.5	15–36	0	0	100	t_(71.8) = 17.79 P < 0.0001
7	24.3	19–32	0.3	0–2	99.0	t_(71.8) = 17.07 P < 0.0001
14	27.4	11–42	0.6	0–2	97.7	t_(71.8) = 15.85 P < 0.0001
21	25.4	15–37	0.4	0–2	98.5	t_(71.8) = 16.67 P < 0.0001
28	24.4	18–32	0.6	0–3	97.4	t_(71.8) = 16.09 P < 0.0001
35	26.4	19–35	0.8	0–2	97.2	t_(71.8) = 15.55 P < 0.0001

Note: Dogs infested with ticks from colony originated with ticks from France and subsequently enriched with ticks from France and Greece, the last time 1 year before study conduct
^aMean live tick count significantly lower than placebo (15.55 ≤ t_71.8 ≤ 17.79, P < 0.0001) at all time-points

ISSN: 1756-3305